AAAAAA

   
Results: 1-8 |
Results: 8
Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: Genotypic and phenotypic analyses of study GS-96-408
Authors: Miller, MD Margot, NA Lamy, PD Fuller, MD Anton, KE Mulato, AS Cherrington, JM
Citation: Md. Miller et al., Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: Genotypic and phenotypic analyses of study GS-96-408, J ACQ IMM D, 27(5), 2001, pp. 450-458
Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults
Authors: Barditch-Crovo, P Deeks, SG Collier, A Safrin, S Coakley, DF Miller, M Kearney, BP Coleman, RL Lamy, PD Kahn, JO McGowan, I Lietman, PS
Citation: P. Barditch-crovo et al., Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults, ANTIM AG CH, 45(10), 2001, pp. 2733-2739
In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA
Authors: Wainberg, MA Miller, MD Quan, YD Salomon, H Mulato, AS Lamy, PD Margot, NA Anton, KE Cherrington, JM
Citation: Ma. Wainberg et al., In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA, ANTIVIR TH, 4(2), 1999, pp. 87-94
Quantitative changes in cytomegalovirus DNAemia and genetic analysis of the UL97 and UL54 genes in AIDS patients receiving cidofovir following ganciclovir therapy
Authors: Bowen, EF Cherrington, JM Lamy, PD Griffiths, PD Johnson, MA Emery, VC
Citation: Ef. Bowen et al., Quantitative changes in cytomegalovirus DNAemia and genetic analysis of the UL97 and UL54 genes in AIDS patients receiving cidofovir following ganciclovir therapy, J MED VIROL, 58(4), 1999, pp. 402-407
9-[2-(phosphonomethoxy)propyl]adenine (PMPA) therapy prolongs survival of infant macaques inoculated with simian immunodeficiency virus with reduced susceptibility to PMPA
Authors: Van Rompay, KKA Cherrington, JM Marthas, ML Lamy, PD Dailey, PJ Canfield, DR Tarara, RP Bischofberger, N Pedersen, NC
Citation: Kka. Van Rompay et al., 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) therapy prolongs survival of infant macaques inoculated with simian immunodeficiency virus with reduced susceptibility to PMPA, ANTIM AG CH, 43(4), 1999, pp. 802-812
Early short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine treatment favorably alters the subsequent disease course in simian immunodeficiency virus-infected newborn rhesus macaques
Authors: Van Rompay, KKA Dailey, PJ Tarara, RP Canfield, DR Aguirre, NL Cherrington, JM Lamy, PD Bischofberger, N Pedersen, NC Marthas, ML
Citation: Kka. Van Rompay et al., Early short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine treatment favorably alters the subsequent disease course in simian immunodeficiency virus-infected newborn rhesus macaques, J VIROLOGY, 73(4), 1999, pp. 2947-2955
Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro
Authors: Miller, MD Anton, KE Mulato, AS Lamy, PD Cherrington, JM
Citation: Md. Miller et al., Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro, J INFEC DIS, 179(1), 1999, pp. 92-100
In vitro antiviral susceptibilities of isolates from cytomegalovirus retinitis patients receiving first- or second-line cidofovir therapy: Relationship to clinical outcome
Authors: Cherrington, JM Fuller, MD Lamy, PD Miner, R Lalezari, JP Nuessle, S Drew, WL
Citation: Jm. Cherrington et al., In vitro antiviral susceptibilities of isolates from cytomegalovirus retinitis patients receiving first- or second-line cidofovir therapy: Relationship to clinical outcome, J INFEC DIS, 178(6), 1998, pp. 1821-1825
Risultati: 1-8 |